CRXT Key Statistics, Chart & Performance
The current stock price of CRXT is 0.099 USD. In the past month the price decreased by -66.21%.
CRXT Latest News, Press Relases and Analysis
CRXT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 47 | 977.11B | ||
| JNJ | JOHNSON & JOHNSON | 19.78 | 494.70B | ||
| MRK | MERCK & CO. INC. | 11.61 | 253.84B | ||
| PFE | PFIZER INC | 7.99 | 145.38B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.77 | 103.74B | ||
| ZTS | ZOETIS INC | 19.33 | 54.02B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.64 | 22.86B | ||
| VTRS | VIATRIS INC | 4.65 | 12.49B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.1 | 11.02B | ||
| CORT | CORCEPT THERAPEUTICS INC | 95.08 | 8.80B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.45B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.30B |
Related stock screener links
About CRXT
Company Profile
Clarus Therapeutics Holdings, Inc. is a pharmaceutical company, which engages in developing androgen and metabolic therapies for men and women, including potential therapies for orphan indications. The company is headquartered in Northbrook, Illinois and currently employs 16 full-time employees. The company went IPO on 2020-12-17. The firm is focused on the commercialization of JATENZO, an oral T-replacement, or T-replacement therapy (TRT). The Company’s lead product, JATENZO, an androgen indicated for T-replacement therapy to treat adult men with hypogonadism due to certain medical conditions. In addition, JATENZO focuses on the classic signs and symptoms associated with hypogonadism, including psychosexual symptoms, body mass index, fat mass and bone mineral density. The firm plans to focused on the development and commercialization of T and metabolic therapies for men and women.
Company Info
CLARUS THERAPEUTICS HOLDINGS
555 Skokie Boulevard, Suite 340
Northbrook ILLINOIS US
CEO: Joseph Hernandez
Employees: 16
Phone: 16463030737.0
CLARUS THERAPEUTICS HOLDINGS / CRXT FAQ
What does CRXT do?
Clarus Therapeutics Holdings, Inc. is a pharmaceutical company, which engages in developing androgen and metabolic therapies for men and women, including potential therapies for orphan indications. The company is headquartered in Northbrook, Illinois and currently employs 16 full-time employees. The company went IPO on 2020-12-17. The firm is focused on the commercialization of JATENZO, an oral T-replacement, or T-replacement therapy (TRT). The Company’s lead product, JATENZO, an androgen indicated for T-replacement therapy to treat adult men with hypogonadism due to certain medical conditions. In addition, JATENZO focuses on the classic signs and symptoms associated with hypogonadism, including psychosexual symptoms, body mass index, fat mass and bone mineral density. The firm plans to focused on the development and commercialization of T and metabolic therapies for men and women.
What is the stock price of CLARUS THERAPEUTICS HOLDINGS today?
The current stock price of CRXT is 0.099 USD. The price decreased by -36.94% in the last trading session.
What is the dividend status of CLARUS THERAPEUTICS HOLDINGS?
CRXT does not pay a dividend.
How is the ChartMill rating for CLARUS THERAPEUTICS HOLDINGS?
CRXT has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is CRXT stock listed?
CRXT stock is listed on the Nasdaq exchange.
Is CLARUS THERAPEUTICS HOLDINGS (CRXT) expected to grow?
The Revenue of CLARUS THERAPEUTICS HOLDINGS (CRXT) is expected to grow by 35.11% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the employee count for CRXT stock?
CLARUS THERAPEUTICS HOLDINGS (CRXT) currently has 16 employees.
CRXT Technical Analysis
CRXT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CRXT. CRXT has a bad profitability rating. Also its financial health evaluation is rather negative.
CRXT Financial Highlights
Over the last trailing twelve months CRXT reported a non-GAAP Earnings per Share(EPS) of -1.27. The EPS increased by 43.66% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -193% | ||
| ROA | -66.68% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
CRXT Forecast & Estimates
9 analysts have analysed CRXT and the average price target is 3.06 USD. This implies a price increase of 2990.91% is expected in the next year compared to the current price of 0.099.
For the next year, analysts expect an EPS growth of 87.39% and a revenue growth 35.11% for CRXT